[ad_1]
Moderna shares are up more than 8% today after the company revealed a single injection vaccine booster for Covid and influenza.
Moderna develops single-injection vaccine against influenza and coronavirus
Moderna has been one of the top performing companies in recent months. The company’s share price soared today after announcing the recall of the single-injection vaccine for Covid and influenza. Shooting should make things a lot easier for people.
The new vaccine, which Moderna calls mRNA-1073, combines the company’s current Covid vaccine with an influenza vaccine in development. CEO Stéphane Bancel said that “Today, we are announcing the first step of our new respiratory vaccine program with the development of a single dose vaccine that combines a COVID-19 booster and an influenza booster.”
She added that Moderna was making progress in enrolling patients in its rare disease programs. In addition, the company is fully enrolled in its personalized cancer vaccine trial. The CEO said they believe it is the start of a new era of information-based drugs.
Moderna has been one of the leading companies in terms of the Covid vaccine. The company recently launched its mRNA-based two-dose Covid vaccine after obtaining approval from the Food and Drug Administration last year. So far, nearly 150 million Moderna shots have been administered in the United States.
Moderna share price rose more than 8%
Moderna shares have rallied since the company announced the launch of its single injection vaccine booster for Covid and influenza. MRNA is up 8% so far today, making it one of the top performing stocks on the market.
MRNA is currently trading at $ 456 per share after its last rally. Since the start of the year, MRNA has been one of the best performing stocks on the market. It started in 2021 at $ 111 a piece, but has now grown over 300% since then.
This article originally appeared on FX Empire
More from FXEMPIRE:
[ad_2]
Source link